206 related articles for article (PubMed ID: 24022228)
1. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL
Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228
[TBL] [Abstract][Full Text] [Related]
2. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
3. Twice-monthly administration of a lower dose of epoetin beta pegol can maintain adequate hemoglobin levels in hemodialysis patients.
Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M
Ther Apher Dial; 2015 Apr; 19(2):138-43. PubMed ID: 25402974
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
[TBL] [Abstract][Full Text] [Related]
5. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.
Dellanna F; Winkler RE; Bozkurt F; Schettler V; Graf S; Bockreiss N; Fliser D;
Int J Clin Pract; 2011 Jan; 65(1):64-72. PubMed ID: 21091595
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia.
Locatelli F; Mandolfo S; Menegato Adorati M; Villa G; Tarchini R; Pizzarelli F; Conte F; Guastoni C; Ricciardi B; Crotta A
J Nephrol; 2013; 26(6):1114-21. PubMed ID: 24052462
[TBL] [Abstract][Full Text] [Related]
7. Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients.
González MT; Ramos R; Vera M; Barbosa F; Garcia C; Garcia I; González-Segura C; Cuxart M; Teixidó J; José de la Cruz J
Ren Fail; 2013; 35(3):314-9. PubMed ID: 23356501
[TBL] [Abstract][Full Text] [Related]
8. Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.
Furukawa T; Okada K; Abe M; Tei R; Oikawa O; Maruyama N; Maruyama T
Int J Mol Sci; 2015 Dec; 16(12):30181-9. PubMed ID: 26694377
[TBL] [Abstract][Full Text] [Related]
9. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients.
Minutolo R; Zamboli P; Chiodini P; Mascia S; Vitiello S; Stanzione G; Bertino V; Conte G; De Nicola L
Blood Purif; 2010; 30(3):186-94. PubMed ID: 20924174
[TBL] [Abstract][Full Text] [Related]
10. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
[TBL] [Abstract][Full Text] [Related]
13. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
Spinowitz B; Coyne DW; Lok CE; Fraticelli M; Azer M; Dalal S; Villa G; Rosansky S; Adamis H; Beyer U;
Am J Nephrol; 2008; 28(2):280-9. PubMed ID: 18004064
[TBL] [Abstract][Full Text] [Related]
14. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
15. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
16. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients.
Weinreich T; Leistikow F; Hartmann HG; Vollgraf G; Dellanna F;
Hemodial Int; 2012 Jan; 16(1):11-9. PubMed ID: 22098689
[TBL] [Abstract][Full Text] [Related]
17. Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis.
Vankar SG; Dutta P; Kohli HS; Bhansali A
Indian J Med Res; 2014 Jan; 139(1):112-6. PubMed ID: 24604046
[TBL] [Abstract][Full Text] [Related]
18. A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA.
Nainan GK; Pathak VR; Dalal SS; Saxena S; Mittal D; Raju TR; Gokulnath ; Isaac R; Rajapurkar MM; Rana DS; Shah BV; Ray DS; Thiagarajan CM; Jha RM; Kukreja AA; Pophale RR
J Assoc Physicians India; 2014 Mar; 62(3):232-6. PubMed ID: 25327065
[TBL] [Abstract][Full Text] [Related]
19. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
20. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
